

Robert J Grimer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3118627/publications.pdf>

Version: 2024-02-01

51
papers

2,983
citations

257450

24
h-index

206112

48
g-index

52
all docs

52
docs citations

52
times ranked

2746
citing authors

#	ARTICLE	IF	CITATIONS
1	Development and comparison of 1-year survival models in patients with primary bone sarcomas: External validation of a Bayesian belief network model and creation and external validation of a new gradient boosting machine model. <i>SAGE Open Medicine</i> , 2022, 10, 205031212210763.	1.8	0
2	Intralesional margin after excision of a high-grade osteosarcoma: Is it a catastrophe?. <i>Journal of Surgical Oncology</i> , 2022, , .	1.7	3
3	Impact of NICE guidelines on the survival of patients with soft-tissue sarcomas. <i>Bone and Joint Journal</i> , 2021, 103-B, 569-577.	4.4	6
4	Denosumab in giant cell tumour of bone in the pelvis and sacrum: Long-term therapy or bone resection?. <i>Journal of Orthopaedic Science</i> , 2020, 25, 513-519.	1.1	24
5	Female gender in the hormonally active age group plays a major role in high-grade chondrosarcoma survival. <i>Acta Oncologica</i> , 2020, 59, 242-246.	1.8	6
6	The importance of surgical margins in malignant Triton tumour of the trunk and extremities. <i>Oncology Letters</i> , 2020, 21, 120.	1.8	3
7	Synovial sarcoma: Do children do better?. <i>European Journal of Surgical Oncology</i> , 2019, 45, 254-260.	1.0	33
8	Surgical treatment for pelvic Ewing sarcoma: What is a safe and functional acetabular reconstruction when combined with modern multidisciplinary treatments?. <i>Journal of Surgical Oncology</i> , 2019, 120, 985-993.	1.7	20
9	Inadvertent excision of malignant soft tissue tumours. <i>EFORT Open Reviews</i> , 2019, 4, 321-329.	4.1	24
10	Denosumab in patients with giant-cell tumour of bone: a multicentre, open-label, phase 2 study. <i>Lancet Oncology</i> , The, 2019, 20, 1719-1729.	10.7	143
11	Silver-coated (Agluna®) tumour prostheses can be a protective factor against infection in high risk failure patients. <i>European Journal of Surgical Oncology</i> , 2019, 45, 704-710.	1.0	19
12	Denosumab treatment of inoperable or locally advanced giant cell tumor of bone – Multicenter analysis outside clinical trial. <i>European Journal of Surgical Oncology</i> , 2018, 44, 1384-1390.	1.0	70
13	Assessment of denosumab treatment effects and imaging response in patients with giant cell tumor of bone. <i>World Journal of Surgical Oncology</i> , 2018, 16, 191.	1.9	39
14	High complication rate after extendible endoprosthetic replacement of the proximal tibia: a retrospective study of 42 consecutive children. <i>Monthly Notices of the Royal Astronomical Society: Letters</i> , 2018, 89, 678-682.	3.3	15
15	When Do Orthopaedic Oncologists Consider the Implantation of Expandable Prostheses in Bone Sarcoma Patients?. <i>Sarcoma</i> , 2018, 2018, 1-6.	1.3	9
16	The role of surgical margins in chondrosarcoma. <i>European Journal of Surgical Oncology</i> , 2018, 44, 1412-1418.	1.0	73
17	Could Routine Magnetic Resonance Imaging Detect Local Recurrence of Musculoskeletal Sarcomas Earlier? A Cost-effectiveness Study. <i>Indian Journal of Orthopaedics</i> , 2018, 52, 81-86.	1.1	6
18	Proximal Tibia Reconstruction After Bone Tumor Resection: Are Survivorship and Outcomes of Endoprosthetic Replacement and Osteoarticular Allograft Similar?. <i>Clinical Orthopaedics and Related Research</i> , 2017, 475, 676-682.	1.5	74

#	ARTICLE	IF	CITATIONS
19	Can a Bayesian Belief Network Be Used to Estimate 1-year Survival in Patients With Bone Sarcomas?. <i>Clinical Orthopaedics and Related Research</i> , 2017, 475, 1681-1689.	1.5	14
20	Outcome of surgery for primary and recurrent desmoid-type fibromatosis. A retrospective case series of 174 patients. <i>Annals of Medicine and Surgery</i> , 2017, 17, 14-19.	1.1	22
21	Can postoperative radiotherapy be omitted in localised standard-risk Ewing sarcoma? An observational study of the Euro-E.W.I.N.G group. <i>European Journal of Cancer</i> , 2016, 61, 128-136.	2.8	69
22	Current status and unanswered questions on the use of Denosumab in giant cell tumor of bone. <i>Clinical Sarcoma Research</i> , 2016, 6, 15.	2.3	80
23	Functional and quality of life outcomes in bone sarcoma following amputation, rotationplasty or limb-salvage. <i>Expert Review of Quality of Life in Cancer Care</i> , 2016, 1, 303-312.	0.6	6
24	An epidemiological survey of tumour or tumour like conditions in the scapula and periscapular region. <i>Sicot-j</i> , 2016, 2, 34.	1.8	18
25	Outcome and the effect of age and socioeconomic status in 1318 patients with synovial sarcoma in the English National Cancer Registry: 1985-2009. <i>Clinical Sarcoma Research</i> , 2016, 6, 18.	2.3	21
26	UK guidelines for the management of bone sarcomas. <i>Clinical Sarcoma Research</i> , 2016, 6, 7.	2.3	163
27	Survival following Pulmonary Metastasectomy for Sarcoma. <i>Thoracic and Cardiovascular Surgeon</i> , 2016, 64, 146-149.	1.0	41
28	Conference report on the 28th annual meeting of the European Musculo-Skeletal Oncology Society, 29 April-1 May 2015, Athens. <i>Ecancermedalscience</i> , 2015, 9, 550.	1.1	0
29	Saving a Child's Elbow Joint: A Novel Reconstruction for a Tumour of the Distal Humerus. <i>Case Reports in Orthopedics</i> , 2015, 2015, 1-5.	0.3	4
30	Extracorporeally irradiated clavicle as an autograft in tumour surgery. <i>Journal of Surgical Case Reports</i> , 2015, 2015, rju151-rju151.	0.4	2
31	Mesenchymal chondrosarcoma: Prognostic factors and outcome in 113 patients. A European Musculoskeletal Oncology Society study. <i>European Journal of Cancer</i> , 2015, 51, 374-381.	2.8	133
32	Surgical Downstaging in an Open-Label Phase II Trial of Denosumab in Patients with Giant Cell Tumor of Bone. <i>Annals of Surgical Oncology</i> , 2015, 22, 2860-2868.	1.5	142
33	Synovial Chondrosarcoma Arising in Synovial Chondromatosis. <i>Sarcoma</i> , 2014, 2014, 1-4.	1.3	67
34	Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 study. <i>Lancet Oncology</i> , The, 2013, 14, 901-908.	10.7	487
35	Can postoperative radiotherapy be omitted in localized standard-risk Ewing sarcoma? An observational study of the Euro-EWING Group.. <i>Journal of Clinical Oncology</i> , 2013, 31, 10518-10518.	1.6	5
36	UK Guidelines for the Management of Bone Sarcomas. <i>Sarcoma</i> , 2010, 2010, 1-14.	1.3	65

#	ARTICLE	IF	CITATIONS
37	Dedifferentiated chondrosarcoma: Prognostic factors and outcome from a European group. <i>European Journal of Cancer</i> , 2007, 43, 2060-2065.	2.8	197
38	Coccydynia: reply to letter by Foye. <i>International Orthopaedics</i> , 2007, 31, 429-429.	1.9	0
39	Size Matters for Sarcomas!. <i>Annals of the Royal College of Surgeons of England</i> , 2006, 88, 519-524.	0.6	164
40	Surgical options for children with osteosarcoma. <i>Lancet Oncology</i> , The, 2005, 6, 85-92.	10.7	193
41	Periosteal osteosarcoma – a European review of outcome. <i>European Journal of Cancer</i> , 2005, 41, 2806-2811.	2.8	101
42	Two-Stage Revision for Infected Endoprostheses Used in Tumor Surgery. <i>Clinical Orthopaedics and Related Research</i> , 2002, 395, 193-203.	1.5	107
43	Diagnosing Musculoskeletal Tumours. <i>Sarcoma</i> , 2001, 5, 89-94.	1.3	28
44	Quality of Life Implications as a Consequence of Surgery: Limb Salvage, Primary and Secondary Amputation. <i>Sarcoma</i> , 2001, 5, 189-195.	1.3	109
45	Wound Complications Following Resection of Adductor Compartment Tumours. <i>Sarcoma</i> , 2001, 5, 203-207.	1.3	16
46	The Two-Stage Ipsilateral Fibular Transfer for Tibial Defect Following Tumour Excision. <i>Sarcoma</i> , 2000, 4, 27-30.	1.3	11
47	MDR1 Gene Expression and Outcome in Osteosarcoma: A Prospective, Multicenter Study. <i>Journal of Clinical Oncology</i> , 2000, 18, 2685-2694.	1.6	80
48	Bilateral Endoprosthetic Replacements of the Proximal Femur. <i>Sarcoma</i> , 1998, 2, 49-51.	1.3	1
49	Longitudinal Growth Following Treatment for Osteosarcoma. <i>Sarcoma</i> , 1998, 2, 115-119.	1.3	12
50	Quality of Life in Children Following Treatment for a Malignant Primary Bone Tumour Around the Knee. <i>Sarcoma</i> , 1997, 1, 39-45.	1.3	47
51	Amplification and Over-Expression of theMDM2Gene in Human Soft Tissue Tumours. <i>Sarcoma</i> , 1997, 1, 17-22.	1.3	11